On Monday, Beam Therapeutics Inc (NASDAQ: BEAM) was -9.80% drop from the session before settling in for the closing price of $28.48. A 52-week range for BEAM has been $20.84 – $38.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 43280.87% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -6.22%. With a float of $73.69 million, this company’s outstanding shares have now reached $83.63 million.
In an organization with 483 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 74.05%, operating margin of -654.25%, and the pretax margin is -593.06%.
Beam Therapeutics Inc (BEAM) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Beam Therapeutics Inc stocks. The insider ownership of Beam Therapeutics Inc is 11.95%, while institutional ownership is 83.36%. The most recent insider transaction that took place on Feb 18 ’25, was worth 220,045. In this transaction SVP, Finance and Treasurer of this company sold 6,287 shares at a rate of $35.00, taking the stock ownership to the 37,527 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Legal Officer sold 10,000 for $34.00, making the entire transaction worth $340,000. This insider now owns 102,968 shares in total.
Beam Therapeutics Inc (BEAM) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.20% during the next five years compared to -20.88% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
You can see what Beam Therapeutics Inc (BEAM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 33.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.58, a number that is poised to hit -1.22 in the next quarter and is forecasted to reach -4.89 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Let’s dig in a bit further. During the last 5-days, its volume was 3.04 million. That was better than the volume of 1.49 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 41.89%. Additionally, its Average True Range was 2.47.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 32.27%, which indicates a significant increase from 18.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.85% in the past 14 days, which was lower than the 74.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.06, while its 200-day Moving Average is $25.80. However, in the short run, Beam Therapeutics Inc’s stock first resistance to watch stands at $27.82. Second resistance stands at $29.96. The third major resistance level sits at $31.85. If the price goes on to break the first support level at $23.79, it is likely to go to the next support level at $21.90. The third support level lies at $19.76 if the price breaches the second support level.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
There are 83,688K outstanding shares of the company, which has a market capitalization of 2.15 billion. As of now, sales total 63,520 K while income totals -376,740 K. Its latest quarter income was 30,070 K while its last quarter net income were -90,350 K.
